7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Mizukami J et al. | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. | 2002 | Mol. Cell. Biol. | pmid:11809792 |
Mochizuki S et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. | 2002 | J. Bone Miner. Metab. | pmid:11810411 |
Childs LM et al. | In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. | 2002 | J. Bone Miner. Res. | pmid:11811549 |
Holloway WR et al. | Leptin inhibits osteoclast generation. | 2002 | J. Bone Miner. Res. | pmid:11811550 |
Coen G et al. | Serum osteoprotegerin and renal osteodystrophy. | 2002 | Nephrol. Dial. Transplant. | pmid:11812872 |
Viereck V et al. | Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. | 2002 | J. Cell. Biochem. | pmid:11835398 |
Wise GE et al. | Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. | 2002 | Arch. Oral Biol. | pmid:11839361 |
Scatena M and Giachelli C | The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. | 2002 | Trends Cardiovasc. Med. | pmid:11852256 |
Hofbauer LC and Kühne CA | Cytokine inhibition: a new therapeutic avenue for skeletal diseases. | 2002 | Drug Discov. Today | pmid:11854049 |
Viereck V et al. | Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. | 2002 | Biochem. Biophys. Res. Commun. | pmid:11855844 |
Romas E et al. | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. | 2002 | Bone | pmid:11856640 |
Theill LE et al. | RANK-L and RANK: T cells, bone loss, and mammalian evolution. | 2002 | Annu. Rev. Immunol. | pmid:11861618 |
Roux S et al. | RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. | 2002 | Am. J. Clin. Pathol. | pmid:11863217 |
Green EA et al. | Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. | 2002 | Immunity | pmid:11869680 |
Faucheux C et al. | Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. | 2002 | J. Bone Miner. Res. | pmid:11874237 |
Kazama JJ et al. | Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. | 2002 | Am. J. Kidney Dis. | pmid:11877571 |
Haas M et al. | Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. | 2002 | Am. J. Kidney Dis. | pmid:11877577 |
Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
Holen I et al. | Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. | 2002 | Cancer Res. | pmid:11912131 |
Mori H et al. | RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. | 2002 | Histochem. Cell Biol. | pmid:11914926 |
Goater JJ et al. | Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. | 2002 | J. Orthop. Res. | pmid:11918293 |
Roux S et al. | RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. | 2002 | Br. J. Haematol. | pmid:11918537 |
Oshiro T et al. | Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. | 2002 | Anat. Rec. | pmid:11920384 |
Redlich K et al. | Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. | 2002 | Arthritis Rheum. | pmid:11920416 |
Khosla S et al. | Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. | 2002 | J. Clin. Endocrinol. Metab. | pmid:11932280 |
Kanematsu M et al. | Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. | 2002 | Bone | pmid:11934645 |
Li X et al. | Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. | 2002 | Bone | pmid:11934647 |
Jain RG and Lenhard JM | Select HIV protease inhibitors alter bone and fat metabolism ex vivo. | 2002 | J. Biol. Chem. | pmid:11937496 |
Schoppet M et al. | RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. | 2002 | Arterioscler. Thromb. Vasc. Biol. | pmid:11950689 |
Ariyasu T et al. | Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. | 2002 | In Vitro Cell. Dev. Biol. Anim. | pmid:11963965 |
Bateman TA and Countryman S | Osteoprotegerin and bone loss associated with spaceflight. | 2002 | Drug Discov. Today | pmid:11965392 |
Inoue D and Matsumoto T | [Recent advances in basic research of bone metabolism]. | 2002 | Nippon Rinsho | pmid:11979916 |
Suzuki Y et al. | [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. | 2002 | Nippon Rinsho | pmid:11979937 |
Inoue D | [Recent advances in research of bone resorption]. | 2002 | Nippon Rinsho | pmid:11979946 |
Udagawa N and Takahashi N | [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. | 2002 | Nippon Rinsho | pmid:11979968 |
Tsuda E | [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. | 2002 | Nippon Rinsho | pmid:11979969 |
Koshihara Y | [Recent progress of bone cell culture system (review)]. | 2002 | Nippon Rinsho | pmid:11979973 |
Hasegawa T et al. | Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. | 2002 | Tissue Cell | pmid:11989970 |
Evdokiou A et al. | Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. | 2002 | Int. J. Cancer | pmid:11992538 |
Corey E et al. | Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. | 2002 | Prostate | pmid:11992617 |
Gruber R et al. | Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. | 2002 | Bone | pmid:11996911 |
de Hooge AS et al. | Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. | 2002 | Am. J. Pathol. | pmid:12000725 |
Bosshart H | Expression of survival receptors in Hodgkin disease cell lines. | 2002 | Blood | pmid:12001908 |
Ono K et al. | Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. | 2002 | J. Bone Miner. Res. | pmid:12009007 |
Iida-Klein A et al. | Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. | 2002 | J. Bone Miner. Res. | pmid:12009011 |
Jiang Y et al. | Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. | 2002 | Infect. Immun. | pmid:12011008 |
Granchi D et al. | Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. | 2002 | Biomaterials | pmid:12013183 |
Li X et al. | Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. | 2002 | Prostaglandins Other Lipid Mediat. | pmid:12013525 |
Treuheit MJ et al. | Inverse relationship of protein concentration and aggregation. | 2002 | Pharm. Res. | pmid:12033388 |
Lossdörfer S et al. | Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. | 2002 | Calcif. Tissue Int. | pmid:12043011 |
Ueland T et al. | Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12050246 |
Sasaki N et al. | Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. | 2002 | Bone | pmid:12052453 |
Brändström H et al. | A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12054556 |
Wittrant Y et al. | Osteoprotegerin differentially regulates protease expression in osteoclast cultures. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12054560 |
Penno H et al. | Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12054622 |
Fu M et al. | Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12056809 |
Zhang J et al. | PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. | 2002 | FEBS Lett. | pmid:12067713 |
Nakamura H et al. | Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. | 2002 | J. Histochem. Cytochem. | pmid:12070273 |
Wynne F et al. | Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. | 2002 | Calcif. Tissue Int. | pmid:12073153 |
Kim YH et al. | Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. | 2002 | Exp. Mol. Med. | pmid:12085990 |
Khosla S et al. | Correlates of osteoprotegerin levels in women and men. | 2002 | Osteoporos Int | pmid:12086350 |
Price PA et al. | Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. | 2002 | J. Bone Miner. Res. | pmid:12096831 |
Xing L et al. | NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. | 2002 | J. Bone Miner. Res. | pmid:12096833 |
Zou W and Bar-Shavit Z | Dual modulation of osteoclast differentiation by lipopolysaccharide. | 2002 | J. Bone Miner. Res. | pmid:12096834 |
Koyama H et al. | Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. | 2002 | J. Bone Miner. Res. | pmid:12096835 |
Langdahl BL et al. | Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. | 2002 | J. Bone Miner. Res. | pmid:12096838 |
Zhang J et al. | Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. | 2002 | J. Bone Miner. Res. | pmid:12096839 |
Saidenberg Kermanac'h N et al. | Osteoprotegerin and inflammation. | 2002 Apr-Jun | Eur. Cytokine Netw. | pmid:12101070 |
Katagiri T and Takahashi N | Regulatory mechanisms of osteoblast and osteoclast differentiation. | 2002 | Oral Dis | pmid:12108759 |
Lee SK and Lorenzo JA | Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. | 2002 | Bone | pmid:12110442 |
Shioi A et al. | Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. | 2002 | Circ. Res. | pmid:12114316 |
Lipton A et al. | Serum osteoprotegerin levels in healthy controls and cancer patients. | 2002 | Clin. Cancer Res. | pmid:12114435 |
Biskobing DM et al. | Novel therapeutic options for osteoporosis. | 2002 | Curr Opin Rheumatol | pmid:12118183 |
Whyte MP et al. | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12124406 |
Krane SM | Genetic control of bone remodeling--insights from a rare disease. | 2002 | N. Engl. J. Med. | pmid:12124412 |
Ziolkowska M et al. | High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. | 2002 | Arthritis Rheum. | pmid:12124857 |
Campagnuolo G et al. | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. | 2002 | Arthritis Rheum. | pmid:12124878 |
Sakata M et al. | Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. | 2002 | Cytokine | pmid:12126649 |
Petersson M et al. | Oxytocin stimulates proliferation of human osteoblast-like cells. | 2002 | Peptides | pmid:12126740 |
Grisar J et al. | Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. | 2002 | J. Rheumatol. | pmid:12136902 |
Chen XW et al. | Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12150965 |
Hofbauer LC et al. | Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. | 2002 | Eur. J. Endocrinol. | pmid:12153751 |
Mundy GR | Metastasis to bone: causes, consequences and therapeutic opportunities. | 2002 | Nat. Rev. Cancer | pmid:12154351 |
Lorget F et al. | Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12163011 |
Geoffroy V et al. | High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. | 2002 | Mol. Cell. Biol. | pmid:12167715 |
Uemura H et al. | Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. | 2002 | J. Endocrinol. | pmid:12176675 |
Ragab AA et al. | Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. | 2002 | Am. J. Physiol., Cell Physiol. | pmid:12176725 |
Ulrich-Vinther M et al. | Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. | 2002 | J Bone Joint Surg Am | pmid:12177271 |
Ohmori H et al. | Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. | 2002 | J. Hum. Genet. | pmid:12181640 |
Armstrong AP et al. | A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. | 2002 | J. Biol. Chem. | pmid:12185073 |
Cundy T et al. | A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. | 2002 | Hum. Mol. Genet. | pmid:12189164 |
Lee SK et al. | 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. | 2002 | J. Immunol. | pmid:12193704 |
Fujita T et al. | SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. | 2002 | J. Oral Pathol. Med. | pmid:12201246 |
Juji T et al. | A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. | 2002 | J. Bone Miner. Metab. | pmid:12203031 |
Jono S et al. | Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. | 2002 | Circulation | pmid:12208791 |
Sedger LM et al. | Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. | 2002 | Eur. J. Immunol. | pmid:12209637 |
Hofbauer LC et al. | Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. | 2002 | J. Cell. Biochem. | pmid:12210731 |
Kondo H et al. | Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. | 2002 | J. Bone Miner. Res. | pmid:12211438 |
Hofbauer LC and Schoppet M | Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12213849 |
Arko B et al. | Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12213850 |